{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T04:07:42Z","timestamp":1720238862050},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ijcard.2016.07.206","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T23:42:36Z","timestamp":1470267756000},"page":"1097-1104","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Oral sirolimus: A possible treatment for refractory angina pectoris in the elderly"],"prefix":"10.1016","volume":"222","author":[{"given":"Alexandru","family":"Mischie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Chanseaume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Gaspard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catalina Liliana","family":"Andrei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crina","family":"Sinescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Schiariti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.07.206_bb0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/euhj.2001.2706","article-title":"The problem of chronic refractory angina; report from the ESC joint study group on the treatment of refractory angina","volume":"23","author":"Mannheimer","year":"2002","journal-title":"Eur. Heart J."},{"issue":"2 Suppl.","key":"10.1016\/j.ijcard.2016.07.206_bb0010","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.cjca.2011.07.007","article-title":"Management of patients with refractory angina: Canadian Cardiovascular Society\/Canadian Pain Society joint guidelines","volume":"28","author":"McGillion","year":"2012","journal-title":"Can. J. Cardiol."},{"issue":"32","key":"10.1016\/j.ijcard.2016.07.206_bb0015","first-page":"1","article-title":"Plan and operation of the Third National Health and Nutrition Examination Survey, 1988\u201394. Series 1: programs and collection procedures","volume":"1","author":"National Center for Health Statistics","year":"1994","journal-title":"Vital Health Stat."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0020","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000320217","article-title":"Intracoronary autologous CD34+ stem cell therapy for intractable angina","volume":"117","author":"Wang","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0025","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/eurheartj\/ehl005","article-title":"The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro heart survey of stable angina","volume":"27","author":"Daly","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0002-9149(72)90624-8","article-title":"Natural history of angina pectoris in the Framingham study. Prognosis and survival","volume":"29","author":"Kannel","year":"1972","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0035","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1161\/01.CIR.88.6.2548","article-title":"Prognosis after the onset of coronary heart disease. An investigation of differences in outcome between the sexes according to initial coronary disease presentation","volume":"88","author":"Murabito","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0040","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/0140-6736(92)92619-Q","article-title":"Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group","volume":"340","author":"Juul-Moller","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/oxfordjournals.eurheartj.a014668","article-title":"Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET study group","volume":"17","author":"Dargie","year":"1996","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/oxfordjournals.eurheartj.a014695","article-title":"Effects of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS)","volume":"17","author":"Rehnqvist","year":"1996","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0055","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0060","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0735-1097(03)00951-3","article-title":"7year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy","volume":"42","author":"Henderson","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0065","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/oxfordjournals.eurheartj.a059486","article-title":"Long-term survival in medically treated patients with ischaemic heart disease and prognostic importance of clinical and electrocardiographic data (the Italian CNR Multicentre Prospective Study OD1)","volume":"10","author":"Brunelli","year":"1989","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0070","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jacc.2008.05.051","article-title":"A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease","volume":"52","author":"Schomig","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0075","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0080","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(02)08265-X","article-title":"Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial","volume":"359","author":"IONA Study Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0085","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1053\/euhj.2002.3286","article-title":"Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris. Long-term effects of spinal cord stimulation and coronary artery bypass grafting on quality of life and survival in the ESBY study","volume":"23","author":"Ekre","year":"2002","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0090","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0002-9149(99)00387-2","article-title":"Direct myocardial revascularisation and angiogenesis: how many patients may be eligible?","volume":"84","author":"Mukherjee","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0095","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/14017430802084997","article-title":"Refractory angina pectoris carries a favourable prognosis: a three-year follow-up of 150 patients","volume":"42","author":"R\u00fcck","year":"2008","journal-title":"Scand. Cardiovasc. J."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0100","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ijcard.2009.09.538","article-title":"Fatality, morbidity and quality of life in patients with refractory angina pectoris","volume":"147","author":"Andr\u00e9ll","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0105","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2459\/01.JCM.0000223253.16686.4d","article-title":"Slow coronary flow and stress myocardial perfusion imaging. Different patterns in acute patients","volume":"7","author":"Mangieri","year":"2006","journal-title":"J. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0110","first-page":"1","article-title":"Clinical results of two-year dual antiplatelet percutaneous coronary intervention with paclitaxel-eluting stents: a single centre study","volume":"2","author":"Mangieri","year":"2007","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0115","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2459\/JCM.0b013e328334c7b9","article-title":"Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant'ANna TIrifiban Safety study","volume":"11","author":"Schiariti","year":"2010","journal-title":"J. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2459\/JCM.0b013e32833cdd04","article-title":"Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention","volume":"12","author":"Schiariti","year":"2011","journal-title":"J. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.vph.2013.11.002","article-title":"Decline in platelet count and long-term post-PCI ischemic events: implication of the intra-aortic balloon pump","volume":"60","author":"Schiariti","year":"2014","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0130","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1592\/phco.30.7.639","article-title":"Impact of enhanced external counterpulsation on Canadian Cardiovascular Society angina class in patients with chronic stable angina: a meta-analysis","volume":"30","author":"Shah","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2261-9-13","article-title":"Spinal cord stimulation in the treatment of refractory angina: systematic review and meta-analysis of randomised controlled trials","volume":"9","author":"Taylor","year":"2009","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0140","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1161\/01.CIR.0000130641.08705.45","article-title":"Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload","volume":"109","author":"McMullen","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0145","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/01.hjh.0000239304.01496.83","article-title":"Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis","volume":"24","author":"Gao","year":"2006","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0150","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/ki.2008.690","article-title":"Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure","volume":"75","author":"Siedlecki","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0155","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.ajkd.2008.04.018","article-title":"Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial","volume":"52","author":"Paoletti","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0160","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/eurheartj\/ehn407","article-title":"Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients","volume":"29","author":"Kushwaha","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2003.09.003","article-title":"Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27Kip1-independent pathway","volume":"172","author":"Castro","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0170","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1034\/j.1600-6143.2003.00094.x","article-title":"Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice","volume":"3","author":"Elloso","year":"2003","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0175","doi-asserted-by":"crossref","first-page":"F43","DOI":"10.1152\/ajprenal.00181.2004","article-title":"Effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts","volume":"289","author":"Varghese","year":"2005","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0180","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2007.09.019","article-title":"Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR\u2212\/\u2212 mice despite severe hypercholesterolemia","volume":"198","author":"Mueller","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0185","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.transproceed.2010.03.112","article-title":"Lower homocysteine levels in renal transplant recipients treated with everolimus: a possible link with a decreased cardiovascular risk?","volume":"42","author":"Farsetti","year":"2010","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0190","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.intimp.2007.01.016","article-title":"mTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells","volume":"7","author":"Schreml","year":"2007","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0195","first-page":"959","article-title":"Combination of clopidogrel and everolimus dramatically reduced the development of transplant arteriosclerosis in murine aortic allografts","volume":"23","author":"Eckl","year":"2010","journal-title":"Transpl. Int."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0200","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/01.CIR.0000066282.05411.17","article-title":"Pilot trial of oral rapamycin for recalcitrant restenosis","volume":"107","author":"Brara","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0205","first-page":"1386","article-title":"Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the oral rapamune to inhibit restenosis (ORBIT) study","volume":"44","author":"Waksman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0210","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1136\/hrt.2004.050617","article-title":"Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial)","volume":"91","author":"Rodr\u00edguez","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0215","first-page":"581","article-title":"Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina single-center study (ORAR trial)","volume":"15","author":"Rodriguez","year":"2003","journal-title":"J. Invasive Cardiol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0220","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ccd.20332","article-title":"Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia","volume":"64","author":"Brito","year":"2005","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0225","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.0000138935.17503.35","article-title":"Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the oral sirolimus to inhibit recurrent in-stent stenosis (OSIRIS) trial","volume":"110","author":"Hausleiter","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0230","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.jacc.2005.12.052","article-title":"Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the prospective, randomized oral rapamycin in Argentina (ORAR II) study","volume":"47","author":"Rodriguez","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4244\/EIJV5I2A40","volume":"5","author":"Rodriguez","year":"2009","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0240","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jcin.2009.08.015","article-title":"Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis","volume":"2","author":"Kufner","year":"2009","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0245","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.0000136812.90177.94","article-title":"Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2years: a randomized clinical trial","volume":"110","author":"Keogh","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0250","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.transproceed.2010.07.007","article-title":"Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin","volume":"42","author":"Paoletti","year":"2010","journal-title":"Transplant Proc."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0255","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","article-title":"The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients","volume":"29","author":"Costanzo","year":"2010","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0260","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European renal transplantation study group","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.ijcard.2016.07.206_bb0265","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1067\/mcp.2001.112513","article-title":"Pharmacokinetic interaction between single oral dose of diltiazem and sirolimus in healthy volunteers","volume":"69","author":"Bottiger","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0270","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nrcardio.2013.93","article-title":"Presentation, management, and outcomes of ischaemic heart disease in women","volume":"10","author":"Vaccarino","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0275","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijcard.2012.10.021","article-title":"Adherence to ethical standards in publishing scientific articles: a statement from the International Journal of Cardiology","volume":"161","author":"Shewan","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0280","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/eurheartj\/ehr464","article-title":"Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular journals","volume":"33","author":"Alfonso","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.07.206_bb0285","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/eurheartj\/ehr480","article-title":"Relations between professional medical associations and the health-care industry, concerning scientific communication and continuing medical education: a policy statement from the European Society of Cardiology","volume":"33","author":"ESC Board","year":"2012","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316316011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316316011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T11:49:34Z","timestamp":1530100174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316316011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":57,"alternative-id":["S0167527316316011"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.07.206","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral sirolimus: A possible treatment for refractory angina pectoris in the elderly","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.07.206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}